Role of 18F-flotufolastat PET/CT imaging in men with high-risk prostate cancer following conventional imaging and associated changes in medical management: A phase 3b investigator-initiated trial.

Authors

Zachariah Taylor

Main Line Health, Bryn Mawr, PA

Zachariah Taylor , Ilia Zeltser , Nachum Stollman , Laurence Belkoff

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.

First Author: John Nikitas

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Prostate-specific membrane antigen SPECT-CT in patients with intermediate and high-risk prostate cancer in primary diagnosis: A comparative analysis with ¹⁸F-PSMA PET/CT.

First Author: Joel E. Vargas Ahumada

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis.

First Author: Wesley Robert Armstrong

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.

First Author: Boris A. Hadaschik